CereTom CT for use with a microPET scanner for preclinical PET/CT imaging

CereTom CT 与 microPET 扫描仪配合使用进行临床前 PET/CT 成像

• 批准号: 7594952
• 负责人: Jonathan Paul James Carney
• 金额: $ 46.35万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7594952
• 关键词: Acute Lung Injury; Animal Experimentation; Animal Model; Animals; Award; Beds; Cellular biology; Chronic Obstructive Airway Disease; Clinical; Critical Care; Development; Environment; Foundations; Funding; Human; Hybrids; Hypersensitivity; Image; Immunology; Incidence; Inflammatory; Influenza; Institution; Laboratories; Longitudinal Studies; Lung; Lung diseases; Malignant neoplasm of lung; Medicine; Microbiology; Modeling; Molecular Genetics; National Institute of Allergy and Infectious Disease; PET/CT scan; Pathology; Pharmaceutical Preparations; Physiology; Pulmonary Fibrosis; Radiology Specialty; Request for Proposals; Research; Research Personnel; Resource Sharing; Site; System; Technology; Translational Research; Tuberculosis; Universities; University of Pittsburgh Cancer Institute; Vaccinated; Vaccine Research; Vendor; Work; animal research subject; chemotherapy; cost; design; falls; instrument; mouse model; nonhuman primate; oncology; pre-clinical; protocol development; public health relevance; therapy development

DESCRIPTION (provided by applicant): This proposal requests funds for a newly available CereTom CT scanner and related accessories which allow it to be combined with a preclinical non-human primate microPET P4 scanner in the fashion of hybrid PET/CT systems, giving a true hybrid imaging platform geared specifically towards the imaging of larger subject research animals up to 20kg. The resulting preclinical PET/CT system will be available as a shared resource to researchers at the University of Pittsburgh and other local institutions. Departments within the University that will benefit from the instrument include: Immunology, Microbiology and Molecular Genetics, Cell Biology and Physiology, Radiology, Medicine, in particular the Pulmonary, Allergy, and Critical Care Division, as well as the Center for Vaccine Research and the University of Pittsburgh Cancer Institute. The system will be sited in the University of Pittsburgh P.E.T. Facility in the Department of Radiology. This preclinical system, now available commercially, was developed by the vendors as options to their respective standalone scanners after being identified by the investigators in this proposal as the optimal system for preclinical imaging of non-human primates, given that the only systems available were small animal systems and clinical PET/CT scanners. Initial development was motivated by an imaging proposal for investigating mechanisms of multi-drug chemotherapy in a non-human primate model of tuberculosis. The first system, funded by a Bill and Melinda Gates Foundation award (P.I.: JoAnne Flynn), is located in an Animal Biosafety Level 3 (ABSL3) environment in the Regional Biocontainment Laboratory (RBL), a NIAID-funded initiative that is part of the University of Pittsburgh Center for Vaccine Research. We aim to capitalize on the development of this design by making it available outside of the ABSL3 environment (at biosafety level 2). The major component in terms of cost, the microPET scanner, is already available in the P.E.T. Facility; hence funds are requested only for the CereTom CT and the optional external microPET bed that works with it. Having a system available outside of ABSL3 is essential for applications that do not fall under the ABSL3 rubric; these include oncology, many infectious and inflammatory lung diseases (e.g. COPD, pulmonary fibrosis, including incidence in SIV/SHIV immunocompromized models) and critical care studies such as acute lung injury. Research restricted to the ABSL3 environment such as tuberculosis and highly pathogenic influenza studies will also benefit from the ability to perform corollary ABSL2 studies (e.g. low pathogenic studies and longitudinal studies of vaccinated healthy animals), and the presence of a platform for protocol development and piloting in non-infected animals outside of the restrictive ABSL3 environment. The introduction of the preclinical PET/CT system is expected to have a major impact on research using larger animal models, and will enhance the NIAID RBL initiative by providing a complimentary imaging platform at ABSL2 to that at ABSL3. Eight Major User projects from NIH-funded investigators at the University of Pittsburgh that will immediately benefit from this technology are identified. PUBLIC HEALTH RELEVANCE: This proposal is for a unique CT scanner that is to be combined with a preclinical microPET scanner, creating a PET/CT imaging platform geared toward larger research animals including non-human primates. The utility of hybrid PET/CT imaging in the small animal and clinical realms is well established. This system will help facilitate translational research and therapy development, from mouse models to larger animals and ultimately to humans, for wide variety of pathologies, particularly those of the lung such as COPD, lung cancer, acute lung injury, tuberculosis and influenza.

描述(由申请者提供)：本建议书要求为新推出的CereTom CT扫描仪和相关附件提供资金，使其能够以混合PET/CT系统的方式与临床前非人类灵长类microPET P4扫描仪相结合，从而提供一个真正的混合成像平台，专门针对重量达20公斤的更大的受试者研究动物进行成像。由此产生的临床前PET/CT系统将作为共享资源提供给匹兹堡大学和其他当地机构的研究人员。该大学内将受益于该仪器的部门包括：免疫学、微生物学和分子遗传学、细胞生物学和生理学、放射学、医学，特别是肺部、过敏和重症监护科，以及疫苗研究中心和匹兹堡大学癌症研究所。该系统将安装在匹兹堡大学放射科的体育教学设施中。这一临床前系统现已上市，是供应商开发的，作为各自独立扫描仪的选项，在本提案中被调查人员确定为非人类灵长类动物临床前成像的最佳系统后，考虑到可用的唯一系统是小动物系统和临床PET/CT扫描仪。最初的发展是由一项关于在非人类灵长类结核病模型中研究多药化疗机制的成像建议推动的。第一个系统由比尔和梅琳达·盖茨基金会(P.I.：Joanne Flynn)资助，位于区域生物遏制实验室(RBL)的动物生物安全3级(ABSL3)环境中，该实验室是NIAID资助的倡议，是匹兹堡大学疫苗研究中心的一部分。我们的目标是利用这一设计的发展，使其在ABSL3环境之外(生物安全级别2)可用。就成本而言，主要的部件，即微型PET扫描仪，已经在P.E.T.设施中提供；因此，只需为CereTom CT和与其配合工作的可选外部微型PET床申请资金。拥有ABSL3以外的系统对于不属于ABSL3标准的应用至关重要；这些应用包括肿瘤学、许多感染性和炎症性肺部疾病(例如COPD、肺纤维化，包括SIV/SIV免疫损害模型中的发病率)和重症监护研究，如急性肺损伤。仅限于ABSL3环境的研究，如结核病和高致病性流感研究，也将受益于能够进行必然的ABSL2研究(例如，对接种疫苗的健康动物进行低致病性研究和纵向研究)，以及在限制ABSL3环境之外的非感染动物中提供方案制定和试点的平台。临床前PET/CT系统的推出预计将对使用更大动物模型的研究产生重大影响，并将通过在ABSL2和ABSL3提供一个免费的成像平台来加强NIAID RBL倡议。从美国国立卫生研究院资助的匹兹堡大学研究人员的八个主要用户项目中确定了将立即受益于这项技术的项目。 公共卫生相关性：这项提议是为了设计一种独特的CT扫描仪，它将与临床前的微型PET扫描仪相结合，创建一个面向包括非人类灵长类动物在内的更大研究动物的PET/CT成像平台。混合PET/CT成像在小动物和临床领域的应用已经很好地确立了。这一系统将有助于促进从小鼠模型到大型动物，最终到人类的各种病理疾病的转化性研究和治疗开发，特别是那些肺部疾病，如慢性阻塞性肺病、肺癌、急性肺损伤、结核病和流感。